

Sabin IPV Development

Institute of Medical Biology, Chinese Academy of Medical Sciences

Guoyang Liao

Oct.6, 2015



Outline


Background •

NSTITUTE OF MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES

244


死

- Process and quality controls
- **Phases** I, II and III clinical trials •
- Production licensure
- **Future consideration** •



Global Poliomyelitis (30 Sept. 2015)

Wild Poliovirus & cVDPV Cases¹, Previous 12 Months^{2,3}



¹Excludes viruses detected from environmental surveillance. ²Onset of paralysis 30 September 2014 – 29 September 2015 *cVDPV1 in Madagascar & Ukraine, cVDPV2 in all other countries. NA: most recent case had onset of paralysis prior to rolling 12 months.

³Includes 1 case with onset of paralysis in Guinea but reported in Mali. Official reassignment to Guinea pending.

Data in WHO HQ as of 29 Sept 2015

cVDPV

Total

cVDPV*

1

8

10

19

1

0

1

2

2

22

Onset of most

recent case

20-Jul-15

16-May -15

22-Aug-15

22-Aug-15

13-Dec-14

NA

13-Dec-14

07-Jul-15


07-Jul-15

22-Aug-15

Global Poliomyelitis in 2015(30 Sept. 2015)

Countries	Year-to-date 2015		Year-to-date 2014		Total in 2014		Onset of paralysis of most recent case	
	WPV1	cVDPV	WPV1	cVDPV	WPV1	cVDPV	WPV1	
Afghanistan	12	0	10	0	28	6	22-ASep-15	
Pakistan	32	0	173	19	306	22	22-AUG-15	
Nigeria	0	1	6	17	6	30	24-Jul-14	
Somalia	0	0	5	0	5	0	11-Aug-14	

Circulating Vaccine-Derived Poliovirus Outbreaks (cVDPVs), 2000-2015



ē ICAL

BIOLOGY

0

P

MEDICAL

Global eradication of wild poliovirus type 2 declared Sep. 20, 2015



Declaration

We, the members of the Global Commission for the Certification of Poliomvelitis Eradication, conclude today, 20th September 2015, that indigenous wild poliovirus type 2 has been eradicated worldwide.

Anthony Adams, Chair Supamit Chunsuttiwat Rose Gana F. Leke Yagob Al Mazrou (David M. Salisbury

NSTITUTE

2

2ª

泽

W

4

なしま

泽

ph

MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES



Bali, Indonesia

The Global Commission for the Certification of **Poliomyelitis Eradication** (GCC) has concluded that wild poliovirus type 2 (WPV2) has been eradicated worldwide. With WPV type 3 not being seen anywhere in the world for nearly three years, the programme is seeing exciting strides towards ending polio for

good.

Big Eradication progress

This announcement marks a major landmark.

1) WPV1, WPV2 and WPV3. WPV2 has been disappeared from 1999.

2) WPV3 has not been detected globally since November 2012 (in Nigeria);

F MEDICAL BIOLOGY CHINESE

ACADMY OF MEDICAL SCIENCES

冷既

4

3) the only remaining endemic WPV1 strains are now restricted to Pakistan and Afghanistan.

The WPV2 eradication is also a significant step in preparation for the phased removal of oral polio vaccines (OPVs), beginning with the removal of type 2 oral polio vaccine requiring a switch from using trivalent, planned for April 2016 (tOPV→b0PV). To prepare for the switch in April 2016, require introducing inactivated polio vaccine (IPV, including type I, II, III antigen) in all routine immunization programmes to maintain immunity levels to type 2 polio.

Biosafety requirement is more stringent

At the final stage of eradication of poliomyelitis, the requirement for biosafety is more stringent. GAP III WHO global action plan to minimize poliovirus facilityassociated risk in the post-eradication/post-OPV era has been drafted.

IEDICAL BIOLOGY CHINESE

前

INSTITUTE B OF MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES 新 泽 費 マーセ 物 泽 码 沉 前

Resolution WHA 61.1:WHO calls for expressions of interest in developing Sabin-IPV.

Sabin polioviruses pose less of a threat in the event of an intentional or unintentional release from the production facility. This is a particular concern in low-income countries where the transmissibility of polioviruses is high.

Developing Sabin IPV by Institute of Medical Biology in China



MEDICAL BIOLOGY CHINESE

ACADMY OF

MEDICAL SCIENCES

な

2ª

学院

4


物

冷研

沉所

Overeview of Sabin IPV development in IMB

- Started in 1983 by Dr. Shude Jiang
- Used microcarrier technology since 1994
- Got approval for clinical trials (phase I & II) in 2007
- Started phase I clinical trial in Aug. 2008
- Finished phase II clinical trial in Aug. 2010
- Finished phase III clinical trial in March, 2013
- Got new drug certification in Jan. 14, 2015
- Go into market in July 1, 21015




Bioreactor 550L














Prurification by Chromatography







Purified Poliovirus D Antigen





Virus particle

HPLC



Inactivation by Formalin





NSTITUTE OF MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES

沉


Antisera production


NSTITUTE

OF MEDICAL BIOLOGY CHINESE ACADMY OF


MEDICA


NCES





Standard curve of WHO reference 91/574







These pictures showed individual result from 3 experiments.

Repeatability and clear dose-response relationship between D antigen concentration and OD value can be seen in these pictures.

The potency of sIPV in vivo assay $% \left({{{\mathbf{T}}_{{\mathbf{T}}}} \right)$




Formulation Selection of Sabin IPV by rat immunogenicity in vivo assay





Brief summary of phases I, II and III

广西疫苗临床观察现场分布图




Protocol of clinical trial phase 1

Preparation and quality control of High middle and low doses of trivalent Sabin IPV

After getting qualified report issued by NIDBC and clinical trial protocol approved by Ethic committee

phase 1 130 persons



Infants 90 test group 45 each 15 for low ,middle and high doses 3 times immunization at 2,3 and 4 months Control group 45

MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES

泽

罪

4

学研

沉

前

Children 20 each 10 for middle and high doses sequentially Adult 20 each 10 for middle and high doses sequentially

Safety evaluation and antibody detection in infant groups


Antibody detection before and after immunization

Determination of serum normal values and function of liver and kidney

Placebo control

Adverse events in phase I

NST N	Cuerra	sIPV-L		sIP	'V-M	sIPV-H	
	Groups –	Test	Placebo	Test	Placebo	Test	Placebo
	Adult	/	/	1/10	/	2/10	/
MEDICAL B	Children	/	/	5/10	/	3/10	/
BIOLOGY	Infants	9/15	9/15	6/15	6/15	11/15	3/15
Y CHIN	SAE	0	0	0	0	0	0





Primary Immunogenicity of Sabin IPV in Phase II

INSTITU	Group		Type I		Type II		Type III	
中國醫学科学院醫学生物学研究所		No of infants	GMT	Seroconve rsion (%)	GMT	Seroconver sion (%)	GMT	Seroconver sion (%)
AL BIOLOG	sIPV-H	85	6335	100.00	339	97.65	884	98.82
DEY CHINES	sIPV-M	92	2981	97.83	155	95.65	492	98.91
前空士物 HINESE ACADMY OF	sIPV-L	89	1789	96.63	101	78.65	307	93.26
NY OF ME	OPV	92	3315	100.00	410	100.00	545	100.00
MEDICAL SC	cIPV	91	386	90.11	192	90.11	706	97.80
SCIENCES								

Phase III Clinical Trials

Trial Plan: Random、Blind、Positive control Number: 1200 infants in 2 months old

Group:

MEDICAL BIOLOGY CHINESE

ACADMY OF

sIPV	600 infants	581 at end
wIPV	600 infants	573 at end

Blood:

Before immunization

7 month after third dose

(新日本) Month after third dose 新日本) Lab. Test: Neutrilizing antibody by NIFDC of China



Cross Neutralization

Understand why slected the formulation: 30, 32, 45 DU



Conclusion of clinical trial

The formulation of **sIPV** with **30/32/45 DU per dose for type I/II/III showed good safety and immunogenicity** in clinical trials, which was not inferior to Salk IPV.

GMP、Production and new drug certification

国家食品药品监督管理总局 中华人民共和国 药品 GMP 认证审批件 药品GMP证书 编号: 国药认字 20150013 CERTIFICATE OF GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS 企业名称 中国医学科学院医学生物学研究所 PEOPLE'S REPUBLIC OF CHINA 证书编号: CN20150012 生产地力 昆明新城高新技术产业基地 A1-2 中国医学科学院医学生物学研究所 企业名称: Manufacturer : Institute of Medical Biology Chinese Academy of Medical Sciences 认证范围 Sabin 株脊髓灰质炎灭活疫苗 (Vero 细胞) 昆明新城高新技术产业基地 A1-2 北: titz 受理编号 GMP140135 受理日期 2014年04月30日 Xincheng High-tech Industrial Base A1-2, Kunming Address : 检查时间 2014年12月27日-12月28日 检查人员 孙东,英志芳,张华 Sabin株準備友质後夜活物菌(Vero無胞) 认证范围: Inactivated Poliomyelitis Vaccine, Sabin Strains (Vero cell) Scope of Inspection : 经审核,符合药品 GMP 认证管理有关规定,同意发给《药品 GMP 证书》。 经审查,符合中华人民共和国《药品生产质量管理规范》要求。 认证结论 佛皇/合山上山王 This is to certify that the above-mentioned manufacturer complies with the requirements of Chinese Good Manufacturing Practices for Pharmaceutical Products. CN20150012 证书有效期 2015年02月10日至2020年02月09日 证书编号 有效期至 2020 年 02 月 09 日 附件 药品 GMP 认证检查缺陷项目 This certificate remains valid until 09/02/2020 中国医学科学院医学生物学研究所 主法 云南省食品药品监督管理局,国家食品药品监督管理总局食品药品审核查 发证机关, 抄送 马会中心。 Issued By 备注 Date for Issuing 10/02/2015 2015 理总局 国家食品药品监督管理总局制 CHINA FOOD AND DRUG ADMINISTRATION 国家食品药品监督管理总局 药品注册批件 ìF -13 原始编号: 53130013 受理号: CXSS1300 1300011濱 市局通用名称, Sabin株脊髄灰质炎灭活疫苗 英之名/拉丁名, Inactivated Pollomyellits Vaccine, Sabin Strains 商品名称, 埃必律 481.52. 44. 84. 原始编号: 53130013 本品含有脊髓灰质炎病毒 I、II型Sabin株和III型Pfizer株3个型的灭活 资毒抗原。 证书编号:国药证字S20150002 主要成份 201 203 注意射剂 中请事项 国产药品注册 根据《中华人民共和国药品管理法》,经审 夫见 林客 每瓶0.5m1,每剂量0.5m1。 每剂量含病毒抗原量应不低 F:I型30DU、II型32DU、 注册分类 预防用生物制品13 查, 下述药品符合新药的有关规定, 特发此证。 1294500 老行,员,老师,2住,4岛,一局 25:52.25 24:118 24 个日 药品名称: Sabin株脊髓灰质炎灭活疫苗 审批结论 **主要成份**: 田型Pfizor株3个型的元活病毒拉面 In Parameter () In Par 持有者:中国医学科学院医学生物学研究所 回到福祉在小生的1998年 企业生活了上海市局部通常的1997年 全工业生活。 4.2°生地址, 昆明高新区马金砷街道办事处打盏花街168号 药晶生产企业 国药准宁S20150002 至2020年01月13日 药品批准文号 有效期 药品批准文号 出会 波則 邦月 5年,至2020年01月13日 新药证书编号 国药证字S20150002 新动行证书 中国医学科学院医学生物学研究所 注册标准、说明书及标签 B(+ 14+ 主送 中国医学科学院医学生物 2. 南省金品群品监督管理局, 云南省金品期品检验规, 一时 明元院, 国家药與素负公, 国家金品药品值管管理总局约 案金品初品监督管理总局信息中心, 国家金品局的品监督管理 品局有信息和公司, 国家金品局的品监管管理总局的品监督可 品监管管理点局例律定局。 把送 、监1 国家食品药品监督管理总局 俗注 月日 计册 DOI SHED THE No.1302230

Prodution and Quality Control in the production scale



INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES 國醫学科学院







Future Consideration

- **1. Production capacity**
- 2. Reducing DAg content by intradermal delivery
- 3. DTaP-sIPV or DTaP-sIPV-Hib

1. Capability of production in first phase

Present Scale: 10–12 millions doses each year

Second phase: phase:60 millions doses each year and do WHO PQ.

ACADMY O

NEDICAL SCIENCES

前





2. Reducing DAg content

The DAg needed for types 2 and 3 are more than that for wIPV, therefore need to improve production process to increase yield Study reducing DAg content per dose through different ways:

- 1) Reducing volume per dose (intradermal delivery);
- 2) Using adjuvant;

NSTITUTE OF MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES

泽

のなま

物

泽

科

宛所

3) Reducing number of doses.

Advances in ID **of** Sabin IPV (Bill-Mellinda Gates Foundation OPP1049425)

NSTITUTE OF MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES

2ª

冷眠

4

物

冷研

沉峭

Three Needle free injector



NSTITUTE OF MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES

面容斜谷院

MIT Device training

May 26, 2013



STITUTE OF MEDICAL BIOLOGY CHINESE ACADMY OF MEDICAL SCIENCES

Biojet





Choosing the appropriate injection site.

Training our colleagues to inject the pig.



.

Pharmajet



Reducing DAg content by intradermal delivery (Protection rate after 3rd dose in rats)

INSTITU	Type 1	Type 2	Type 3
Needle ID sIPV 1/	3 100%	100%	100%
Needle ID cIPV 1/	3 70%	100%	90%
Needle ID sIPV 1/	5 100%	100%	100%
Needle ID cIPV 1/	5 65%	100%	90%
Needle free Injex s 1/5	IPV 100%	75%	80%
Needle ID sIPV 1/ Needle ID cIPV 1/ Needle ID sIPV 1/ Needle ID cIPV 1/ Needle ID cIPV 1/ Needle ID cIPV 1/ Needle free Injex s 1/5 Needle free Injex s 1/3 Needle IM sIPV whole dos	IPV 103%	90%	100%
Needle IM sIPV whole dos	age 100%	100%	100%
Needle IM cIPV whole dos	age 100%	100%	100%
(IM NS) control	0	0	0



Summary

- Established production process and quality controls.
- Phases I, II and III clinical trials indicated good safety and immunogenecity.
- Got the certifications of GMP, production and new drug and success into market.

NEDICA L SCIENCES 前

Acknowledgements

Guangxi CDC in China

National Institute for Food and Drug Control

WHO

Bill-Melinda Gates Foundatic USA CDC

NIBSC RIVM



Thanks